Kuno Jung
Keine laufenden Positionen mehr
Profil
Dr. Kuno Jung has eight years experience in the life science and over three years experience in the venture capital industry.
Before joining GLSV, he served as Chief Executive Officer at Timaq medical imaging Inc., a globally active clinical imaging contract research organization since the start of the company in 2003.
Prior to joining Timaq, he co-founded Aravis Ventures in 2001, a life science specific Venture Capital Fund, where he served as investment manager specializing in early-stage Biotech investments which were primarily located in Europe.
From 2000 until 2001 he was Project Manager at LUNAMed AG, Zurich, Switzerland, a cancer therapeutic company.
From 1999 until 2003, he advised a series of Biotech companies for strategic alignment and business development.
For his work with Timaq Medical Imaging Inc., the Swiss Federal Office for Professional Education and Technology (OPET) awarded him the CTI start-up prize in 2004 for the successful build-up of a start-up company.
Kuno holds a PhD in Biotechnology and an MS in food sciences, which he both obtained from the Swiss Federal Institute of Technology (ETH) in Zurich in 1999 and in 1996, respectively.
Ehemalige bekannte Positionen von Kuno Jung
| Unternehmen | Position | Ende |
|---|---|---|
Global Life Science Ventures AG
 Global Life Science Ventures AG Investment ManagersFinance Global Life Science Ventures AG (GLSV-Switzerland) is the Swiss office of the independent venture capital firm which was founded in 1996 with the support of Dr. Stefan Engelhorn. One of the first European venture capital firms to focus exclusively on the life science industry, GLSV-Switzerland advises and manages funds for leading European banks, insurance companies, funds-of-funds and family offices. In addition to their office in Zug, the firm has an office in Munich, Germany. The two offices act as one team with a global perspective, concentrating on their German-speaking home markets and pursuing international partnering opportunities, including investments in the US. GLSV-Switzerland is sensitive to investing in companies with technological or bioethical issues which are still the object of public debate and advises potential investee companies to adhere to core ethical values published in official publications. | Private Equity Investor | - |
Action Pharma A/S
 Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Health Technology |
Global Life Science Ventures AG
Global Life Science Ventures AG Investment ManagersFinance Global Life Science Ventures AG (GLSV-Switzerland) is the Swiss office of the independent venture capital firm which was founded in 1996 with the support of Dr. Stefan Engelhorn. One of the first European venture capital firms to focus exclusively on the life science industry, GLSV-Switzerland advises and manages funds for leading European banks, insurance companies, funds-of-funds and family offices. In addition to their office in Zug, the firm has an office in Munich, Germany. The two offices act as one team with a global perspective, concentrating on their German-speaking home markets and pursuing international partnering opportunities, including investments in the US. GLSV-Switzerland is sensitive to investing in companies with technological or bioethical issues which are still the object of public debate and advises potential investee companies to adhere to core ethical values published in official publications. | Finance |